SLC5A2 and type 2 diabetes mellitus: Similar to SGLT2 inhibitors, although GLP-1RAs were initially designed for glycemic management in patients with type 2 diabetes, their impressive effects beyond glucose control, particularly in reducing cardiovascular risk and promoting weight loss, have prompted consideration of their potential use in patients without concurrent T2DM [31].